5.43  0.08 (1.5%)		04-23 16:00
Open: 4.7 High: 5.75 Volume: 507,292		Pre. Close: 5.35 Low: 4.7 Market Cap: 20(M)

Short term
Mid term
Targets	6-month :	6.71	1-year :	7.84
Resists	First :	5.75	Second :	6.71
Pivot price	4.2
Supports	First :	4.26	Second :	3.33
MAs	MA(5) :	4.74	MA(20) :	4.11
	MA(100) :	2.72	MA(250) :	1.71
MACD	MACD :	0.2	Signal :	0.1
%K %D	K(14,3) :	74.1	D(3) :	60.7
RSI	RSI(14): 66.7
52-week	High :	7.86	Low :	0.34

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ BCTX ] has closed Bollinger Bands are 2.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	5.76 - 5.78	5.78 - 5.8
Low:	4.98 - 5	5 - 5.02
Close:	5.39 - 5.42	5.42 - 5.47

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Wed, 23 Apr 2025
BriaCell Announces Four Clinical Data Presentations at ASCO 2025 - TradingView

Wed, 23 Apr 2025
Major Phase III Breast Cancer Treatment Update: BriaCell Unveils 4 Clinical Studies at ASCO 2025 - Stock Titan

Tue, 22 Apr 2025
BriaCell (BCTX) Advances Phase 3 Trial for Bria-IMT in Metastatic Breast Cancer | BCTX Stock News - GuruFocus

Tue, 22 Apr 2025
Fast-Tracked Phase 3 Breast Cancer Treatment Shows Major Enrollment Surge: 75 Patients Join Critical Trial - Stock Titan

Wed, 16 Apr 2025
BCTX - Briacell Therapeutics Corp Latest Stock News & Market Updates - Stock Titan

Wed, 16 Apr 2025
BriaCell Phase 2 Survival Data Beats Leading Standard in HR+ Breast Cancer - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	4 (M)
Shares Float	3 (M)
Held by Insiders	12.9 (%)
Held by Institutions	14 (%)
Shares Short	188 (K)
Shares Short P.Month	202 (K)

EPS	-4.75
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.22
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-158.2 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-7.33
Qtrly Earnings Growth	0 %
Operating Cash Flow	-22 (M)
Levered Free Cash Flow	-11 (M)

PE Ratio	-1.15
PEG Ratio	0
Price to Book value	4.45
Price to Sales	0
Price to Cash Flow	-0.92

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.